Ovascience, Inc. (OVAS): Michelle Dipp , CEO of Ovascience, Inc. purchased 425,000 shares on Jun 1, 2016. The Insider buying transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.00 per share for a total value of $2,975,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2016, Richard Aldrich (director) purchased 20,000 shares at $7.86 per share price.On May 20, 2016, Michelle Dipp (CEO) purchased 20,000 shares at $7.86 per share price.Also, On May 12, 2016, Paul W.d. Chapman (COO) purchased 3,100 shares at $7.37 per share price.On Oct 7, 2015, Jeffrey E Young (CFO) purchased 3,450 shares at $10.70 per share price.
Shares of OvaScience Inc (OVAS) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.4 points or -5.42% at $6.98 with 6,58,800 shares getting traded. Post opening the session at $7.34, the shares hit an intraday low of $6.86 and an intraday high of $7.34 and the price vacillated in this range throughout the day. The company has a market cap of $191 M and the number of outstanding shares has been calculated to be 2,73,28,779 shares. The 52-week high of OvaScience Inc is $39.29 and the 52-week low is $4.53.
OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of new fertility treatments based on egg precursor or EggPC cells which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.